Francis Knuettel II - 01 Jul 2025 Form 4 Insider Report for Pelthos Therapeutics Inc. (CHRO)

Role: Chief Financial Officer
Signature: /s/ Francis Knuettel II
Issuer symbol: CHRO
Transactions as of: 01 Jul 2025
Net transactions value: +$100,000
Form type: 4
Filing time: 03 Jul 2025, 21:04:18 UTC
Previous filing: 02 Jun 2025
Next filing: 07 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Francis Knuettel II	Chief Financial Officer	C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, DURHAM	/s/ Francis Knuettel II	03 Jul 2025	0001433316

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTHS	Common Stock	Conversion of derivative security	$100,000	+10,000		$10.00	10,000	01 Jul 2025	By Camden Capital LLC	F1, F2
holding	PTHS	Common Stock						12,816	01 Jul 2025	By Lara Knuettel Revocable Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTHS	Series A Convertible Preferred Stock	Other	$0	+10,000		$0.000000	10,000	01 Jul 2025	Common Stock	10,000	$10.00	See footnote	F1, F2, F3, F4
transaction	PTHS	Series A Convertible Preferred Stock	Conversion of derivative security	$0	-10,000	-100%	$0.000000	0	01 Jul 2025	Common Stock	10,000	$10.00	See footnote	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.
F2	Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.
F3	The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.
F4	Acquired in connection with cancellation of promissory note.